Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 85, Issue 2, Pages 131-133Publisher
WILEY
DOI: 10.1038/clpt.2008.223
Keywords
-
Categories
Funding
- Cancer Research UK
- Experimental Cancer Medical Centre
- MRC Biomarker
- National Health Service
Ask authors/readers for more resources
Compared with conventional chemotherapy, rationally designed molecularly targeted agents may be more likely to have antitumor activity in selected tumor subgroups driven by the oncogenic signals targeted by these compounds and a different side-effect profile. The use of biomarkers in the early clinical trials of these new anticancer agents has the potential to increase study participants' benefit from early clinical trials, accelerate the drug development process, maximize the ability to generate important biological information about human cancer, and decrease the risk of late and costly drug attrition.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available